Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2800-2808

  Shor, Audrey C ^a,b   Keschman, Elizabeth A ^a   Lee, Francis Y ^c   Muro Cacho, Carlos ^d   Letson, G Douglas ^a   Trent, Jonathan C ^e   Pledger, W Jack ^a,b   Jove, Richard ^f  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRK ASSOCIATED SUBSTRATE PROTEIN; DASATINIB; FOCAL ADHESION KINASE; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL INVASION; CELL LINE; CELL MIGRATION; CELL SURVIVAL; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EWING SARCOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA;

APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; HUMANS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES;

EID: 34047265691     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3469     Document Type: Article

References (47)

1. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685-94.
2. Jemal A, Tiwari R, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
3. Albritton K. Sarcomas in adolescents and young adults. Hematol Oncol Clin North Am 2005;19:527-46, vii.
4. Bleyer A, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation. Cancer 2005;103:1891-7.
5. Bleyer W. The adolescent gap in cancer treatment. J Registry Manage 1996;23:114-5.
6. Bleyer W, Tejeda H, Murphy S, et al. National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health 1997;21:366-73.
7. Erikson RL, Purchio AF, Erikson E, Collett MS, Brugge JS. Molecular events in cells transformed by Rous Sarcoma virus. J Cell Biol 1980;87:319-25.
8. Jove R, Hanafusa H. Cell transformation by the viral src oncogene. Annu Rev Cell Biol 1987;3:31-56.
9. Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 1911;13: 397-411.
10. Baker B, Fujita D, et al. Genesis of a virus-transforming gene. Natl Cancer Inst Monogr 1978;48:219-223.
11. Gonda TJ, Sheiness DK, Bishop JM. Transcripts from the cellular homologs of retroviral oncogenes: distribution among chicken tissues. Mol Cell Biol 1982;2:617-24.
12. Hu S, Lai M, Vogt P. Characterization of the env gene in avian oncoviruses by heteroduplex mapping. J Virol 1978;27:667-76.
13. Varmus H, Hirai H, Morgan D, Kaplan J, Bishop J. Function, location, and regulation of the src protein-tyrosine kinase. Princess Takamatsu Symp 1989;20:63-70.
14. Neet K, Hunter T. Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1996;1:147-69.
15. Thomas S, Brugge J. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13: 513-609.
16. Brown MT, Cooper JA. Regulation, substrates, and functions of src. Biochim Biophys Acta 1996;1287: 121-49.
17. McLean GW, Carragher NO, Avizienyte E, et al. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005;5:505-15.
18. Parsons J, Parsons S. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol 1997;9:187-92.
19. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002;1602:114-30.
20. McLean GW, Brown K, Arbuckle MI, et al. Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis. Cancer Res 2001;61:8385-9.
21. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Haras during mouse skin carcinogenesis. Nature 1986;322: 78-80.
22. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006;69:1527-33.
23. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-32.
24. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9.
25. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66:473-81.
26. Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006;108: 286-91.
27. Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-8.
28. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methyl- phenyl)-2-(6-(4-(2-hydroxyethyI)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
29. Tremblay L, Hauck W, Aprikian AG, et al. Focal adhesion kinase (pp125FAK) expression, activation, and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 1996;68: 164-71.
30. McCormack SJ, Brazinski SE, Moore JL, Jr., Werness BA, Goldstein DJ. Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene 1997;15: 265-74.
31. Cance WG, Harris JE, Iacocca MV, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000;6:2417-23.
32. Lark A, Livasy C, Calvo B, et al. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res 2003;9: 215-22.
33. McLean GW, Komiyama NH, Serrels B, et al. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev 2004;18:2998-3003.
34. Bouton AH, Riggins RB, Bruce-Staskal PJ. Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene 2001;20: 6448-58.
35. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004;4: 97-105.
36. Defilippi P, Di Stefano P, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 2006;16:257-63.
37. Hanks SK, Ryzhova L, Shin NY, Brabek J. Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci 2003;8:d982-96.
38. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 2001;1540:1-21.
39. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
40. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004;48:8017-23.
41. Yeatman T. A renaissance for SRC. Nat Rev Cancer 2004;4:470-80.
42. Oral BMS-354825 rescues Gleevec-resistant CML. Cancer Biol Ther 2004;3:700.
43. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
44. Doggrell SA. BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin Investig Drugs 2005;14: 89-91.
45. O'Hare T, Corbin A, Druker B. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006;16:92-9.
46. Shah N. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program 2005;1:183-7.
47. Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-7.